SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals inches up on entering into MoU with Government of Republic of Zambia

18 Oct 2024 Evaluate

Akums Drugs & Pharmaceuticals is currently trading at Rs. 915.00, up by 0.25 points or 0.03% from its previous closing of Rs. 914.75 on the BSE.

The scrip opened at Rs. 896.00 and has touched a high and low of Rs. 935.00 and Rs. 896.00 respectively. So far 17573 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 724.50 on 06-Aug-2024.

Last one week high and low of the scrip stood at Rs. 935.00 and Rs. 815.00 respectively. The current market cap of the company is Rs. 14355.12 crore.

The promoters holding in the company stood at 75.26%, while Institutions and Non-Institutions held 14.58% and 10.16% respectively.

Akums Drugs and Pharmaceuticals (Akums) has entered into a Memorandum of Understanding (MoU) with The Government of Republic of Zambia through Ministry of Health situated at Ndeke House, Haile Selassie Road Lusaka in Lusaka Province for Local Manufacturing of Medicines and to recognize the existing collaboration between the Zambian Government and Akums in the field of medicines and medical supplies and to strengthen collaboration between the entities.

Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.


Akums Drugs & Pharma Share Price

530.50 -3.60 (-0.67%)
22-Apr-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1662.40
Dr. Reddys Lab 1212.00
Cipla 1226.00
Zydus Lifesciences 923.75
Lupin 2290.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×